Penumbra, Inc. (NYSE:PEN - Get Free Report) EVP Johanna Roberts sold 600 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00. Following the sale, the executive vice president now directly owns 66,539 shares of the company's stock, valued at approximately $19,125,304.77. This represents a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Penumbra Price Performance
Shares of PEN traded down $2.63 during mid-day trading on Friday, reaching $275.07. The company had a trading volume of 347,006 shares, compared to its average volume of 395,060. The company's 50-day moving average is $267.39 and its 200-day moving average is $235.44. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The company has a market capitalization of $10.59 billion, a P/E ratio of 809.01, a P/E/G ratio of 2.83 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25.
Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $315.52 million for the quarter, compared to analysts' expectations of $311.63 million. On average, equities analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.
Wall Street Analysts Forecast Growth
PEN has been the subject of a number of recent analyst reports. Oppenheimer started coverage on shares of Penumbra in a research note on Tuesday, December 17th. They issued an "outperform" rating and a $275.00 price objective for the company. Canaccord Genuity Group lifted their target price on shares of Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Wells Fargo & Company upped their price target on Penumbra from $275.00 to $305.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. StockNews.com downgraded shares of Penumbra from a "buy" rating to a "hold" rating in a report on Friday, February 28th. Finally, BTIG Research raised their target price on Penumbra from $232.00 to $270.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Penumbra presently has an average rating of "Moderate Buy" and a consensus price target of $292.64.
View Our Latest Analysis on PEN
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in PEN. Quadrant Capital Group LLC raised its position in shares of Penumbra by 6.6% during the fourth quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock worth $150,000 after acquiring an additional 39 shares during the last quarter. Pallas Capital Advisors LLC boosted its position in shares of Penumbra by 3.8% during the fourth quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company's stock worth $263,000 after purchasing an additional 41 shares in the last quarter. Advisors Asset Management Inc. grew its stake in Penumbra by 11.5% in the third quarter. Advisors Asset Management Inc. now owns 416 shares of the company's stock valued at $81,000 after acquiring an additional 43 shares during the period. Baker Avenue Asset Management LP increased its stake in Penumbra by 1.6% during the 4th quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company's stock worth $791,000 after purchasing an additional 53 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in shares of Penumbra by 1.0% during the fourth quarter. Pacer Advisors Inc. now owns 5,721 shares of the company's stock worth $1,359,000 after acquiring an additional 57 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.
About Penumbra
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
See Also

Before you consider Penumbra, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.
While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.